Benzodiazepines - Therapeutic use
Research News and Information

Sunday, November 22, 2009

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

26 Oct 2009 CONTEXT: Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication. OBJECTIVE: To study the association of ... Read more...

Clinical trials design lessons from the CATIE study.

29 Sep 2009 The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study was funded by the National Institute of Mental Health to compare the effectiveness of drugs for schizophrenia. The focus here is not on its conclusions but on the knotty ... Read more...

The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.

29 Sep 2009 Olanzapine is a second-generation antipsychotic that may cause weight gain and metabolic syndrome in some cases. The peroxisome proliferator-activated receptor (PPAR)-gamma is an important gene in the progress of type II diabetes and metabolic ... Read more...

Latest indexed articles for 'Benzodiazepines - Therapeutic use'

These are the very latest articles for this heading:

• Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. 26 Oct 2009
• Seizures in a 9 month old girl. 19 Oct 2009
• Clinical trials design lessons from the CATIE study. 29 Sep 2009
• The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. 29 Sep 2009
• [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists] 30 Aug 2009
• The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. 30 Aug 2009
• Fatal pulmonary embolism following antipsychotic treatment and physical restraint. 30 Aug 2009
• Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. 30 Aug 2009
• Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. 30 Aug 2009
• Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. 30 Aug 2009
• FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. 24 Aug 2009
• The impact of diazepam's discovery on the treatment and understanding of status epilepticus. 6 Aug 2009
• Restless legs syndrome. 30 Jul 2009
• Rational treatment options with AEDs and ketogenic diet in Landau-Kleffner syndrome: still waiting after all these years. 30 Jul 2009
• Potential limitations in generalizing findings from the TORDIA study. 30 Jul 2009
• GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. 14 Jul 2009
• Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 12 Jul 2009
• Haloperidol plus promethazine for psychosis-induced aggression. 6 Jul 2009
• Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. 5 Jul 2009
• Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia. 5 Jul 2009

See a longer list of these articles.

Technical information about 'Benzodiazepines'

Definition: A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring.

Registry Number: 12794-10-4

Descriptor UI: D001569

Alternative terms: Benzodiazepines; Benzodiazepine Compounds; Benzodiazepine;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D03.438.079.080;

History Note: 75

Technical Notes: do not confuse with BENZODIAZEPINONES